Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml
Synfacts 2006(9): 0875-0875
DOI: 10.1055/s-2006-942056
DOI: 10.1055/s-2006-942056
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag Stuttgart · New York
Synthesis of Torcetrapib
D. B. Damon, R. W. Dugger, S. E. Hubbs, J. M. Scott, R. W. Scott*
Pfizer Chemical Research and Development, Groton, USA
Further Information
Publication History
Publication Date:
23 August 2006 (online)
![](https://www.thieme-connect.de/media/synfacts/200609/lookinside/thumbnails/10.1055-s-2006-942056-1.jpg)
Significance
Torcetrapib, the least euphonic drug candidate in living memory, is in clinical trials for the treatment of atherosclerosis because it inhibits cholesteryl ester transfer protein. The six-step synthesis from the commercial enantiopure amine B (37% overall) features a large-scale Pd-catalyzed Buchwald N-arylation as the key step.